Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Elongin C pseudogene 26 (ELOCP26)
- Target
- ELOCP26
- Molecular classification
- Other (Pseudogene)
01
Overview
Elongin C pseudogene 26 (ELOCP26) is a non-protein-coding genomic locus classified as a pseudogene. It bears sequence similarity to the elongin C gene (ELOC/TCEB1), which is a regulatory subunit in the transcriptional elongation complex SIII, playing a role in RNA polymerase II regulation[1][4]. ELOCP26 does not encode a functional protein and is not known to play any role in cellular signaling, disease, or therapeutic intervention[1][7].\n\nKey clarification: The protein-coding gene elongin C (ELOC/TCEB1) is sometimes studied in relation to cancer and oxygen-sensing pathways[4][10], but Elongin C pseudogene 26 (ELOCP26) itself is only a pseudogene and not a biological target.\n\nIf you intended to request information about the active elongin C protein (ELOC/TCEB1), further details are available, but for ELOCP26 the above information fully characterizes its relevance and limitations as a research or therapeutic target[1][7].
- Other names
- ELOC26TCEB1P26
02
Mechanism of action
None; as a pseudogene, it is not a drug target.
03
Biological functions
None established; ELOCP26 does not have documented physiological functions due to its status as a pseudogene
04
Disease associations
None established; no direct disease associations for ELOCP26. The protein-coding gene ELOC (elongin C) is associated with some diseases, but the pseudogene itself is not
05
Safety considerations
None specific; as a non-coding pseudogene, ELOCP26 is not relevant for therapeutic risk.
Beyond the preview
Go deeper on Elongin C pseudogene 26 (ELOCP26).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elongin C pseudogene 26 (ELOCP26).